Harnessing our immune system to fight Alzheimer’s disease

By Lauryn Doherty, guest contributor Canadians are living longer. In 1950, our average life expectancy was about 68 years; in 2023, it has risen to 83 years. Unfortunately, the human body becomes more susceptible to disease as it ages. Alzheimer’s disease is a particular concern because approximately 76,000 new cases are diagnosed in Canada every […]

Continue reading


What we know and don’t know about Alzheimer’s disease

By Michael Ralph Limmena, Health, Medicine & Veterinary Science co-editor Canadians are living longer than ever — 2015 marked the first year that the number of Canadians older than 65 surpassed the number of children younger than 15. Unfortunately, the Alzheimer Society of Canada’s latest projections paint a grim picture for the future for many […]

Continue reading


The controversy behind the new FDA-approved drug for Alzheimer’s disease

image-institute-douglas_cc-by-nc-nd

Rana Semaan, Science in Society editor On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved the drug Aduhelm™ (aducanumab-avwa) for the treatment of Alzheimer’s disease under its accelerated approval pathway. I felt overjoyed and excited reading this news. I’d seen the disease up close and lost my grandmother to Alzheimer’s. I immediately […]

Continue reading